ECS Botanics (ASX:ECS) expands into direct-to-consumer cannabis sales

ECS Botanics Holdings has ventured into direct-to-consumer medicinal cannabis sales, launching with a contract with Elite Medical Solutions.

The deal guarantees $380,000 annually and allows for potential expansion.

ECS introduces soft gel capsules to the Australian market and expands into white label pastilles.

The company has formed a dedicated B2C sales team and plans to launch the AVANI Rapid range in early 2025. It also commenced B2B shipments to German clients.